Key result
ESC secondary prevention adherence post-STEMI remains suboptimal, with only ~31% achieving LDL targets.
Why the study?
Risk factor modification is central following STEMI, but adherence to 2021 ESC secondary-prevention recommendations needed evaluation in rural and remote Far North Queensland.
Observational (n=173)
No
Adherence to ESC secondary prevention targets following STEMI in a rural Australian hospital is suboptimal, highlighting the need for structured secondary-prevention pathways.
Answers are grounded in this paper and cite their sources.
Suboptimal post-STEMI risk-factor control warrants closer outpatient review; leaves open optimal implementation strategies.
Background/Introduction Risk factor modification is central to secondary prevention following ST-elevation myocardial Infarction (STEMI). The 2021 European Society of Cardiology (ESC) guidelines emphasise optimisation of modifiable risk factors - lipids, blood pressure, smoking, diabetes, weight, and cardiac rehabilitation to prevent recurrent events and improve survival.1 Purpose To evaluate adherence to ESC secondary-prevention recommendations among patients admitted with STEMI in 2024 to a hospital which serves rural and remote Far North Queensland. Methods A retrospective audit of all 2024 STEMI patients was performed using hospital electronic records. Each patient’s inpatient baseline was compared with outpatient follow up across smoking status, cessation support, blood pressure (<140/90mmHg), lipids (LDL<1.4mmol/L and/or ≥50% reduction)2, BMI <25kg/m² or ≥5% weight loss, HbA1c review in diabetics³, and cardiac rehabilitation completion. Outcomes were compared to ESC secondary-prevention targets.1,3 Results Among 173 STEMI patients (27.2% Aboriginal or Torres Strait Islander), 102 had follow-up. Smoking was reported in 52.1%, 97% received counselling, 29.1% accepted nicotine replacement, and 12.5% had quit. Blood pressure <140/90mmHg was achieved in 64%, with optimisation in 39%. Lipid re-testing occurred in 54%, 31% had LDL <1.4mmol/L, 36% ≥50% reduction, and 21% met both. Lipid therapy was intensified in 47%, mainly through ezetimibe addition.2 At review, 39% had BMI <25kg/m², 26% achieved ≥5% weight loss, and 43% completed cardiac rehabilitation. Overall, 47% were pre-diabetic or diabetic, 88% of diabetics were discharged on therapy, with HbA1c re-checked in 71% of diabetics and 37.5% of pre-diabetics.3 Conclusion(s) Partial optimisation of risk factors was achieved, however, full adherence to ESC targets – particularly lipid, weight, diabetes, and rehabilitation goals – remained suboptimal. Strengthened follow up and structured secondary-prevention pathways are warranted for these patients.1,3
No takes yet. Share an insight, caveat, or question.
Cherian et al. (2026) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=173). ESC secondary prevention recommendations was evaluated on Adherence to ESC secondary-prevention targets. Adherence to ESC secondary prevention targets following STEMI was suboptimal, with 64% achieving blood pressure <140/90mmHg, 31% achieving LDL <1.4mmol/L, and 43% completing cardiac rehabilitation.
Synapse has enriched 10 related papers. Consider them for comparative context: